Puma Biotechnology (PBYI) Competitors $2.90 -0.02 (-0.68%) Closing price 04:00 PM EasternExtended Trading$2.90 +0.00 (+0.17%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PBYI vs. CGEM, AUTL, VALN, XERS, MAZE, TECX, MGTX, MLYS, TRDA, and RNACShould you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include Cullinan Therapeutics (CGEM), Autolus Therapeutics (AUTL), Valneva (VALN), Xeris Biopharma (XERS), Maze Therapeutics (MAZE), Tectonic Therapeutic (TECX), MeiraGTx (MGTX), Mineralys Therapeutics (MLYS), Entrada Therapeutics (TRDA), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical products" industry. Puma Biotechnology vs. Cullinan Therapeutics Autolus Therapeutics Valneva Xeris Biopharma Maze Therapeutics Tectonic Therapeutic MeiraGTx Mineralys Therapeutics Entrada Therapeutics Cartesian Therapeutics Cullinan Therapeutics (NASDAQ:CGEM) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, community ranking, risk, media sentiment and valuation. Do analysts rate CGEM or PBYI? Cullinan Therapeutics presently has a consensus price target of $32.50, indicating a potential upside of 257.93%. Puma Biotechnology has a consensus price target of $7.00, indicating a potential upside of 142.13%. Given Cullinan Therapeutics' higher probable upside, research analysts plainly believe Cullinan Therapeutics is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cullinan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in CGEM or PBYI? 86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 6.1% of Cullinan Therapeutics shares are owned by insiders. Comparatively, 23.7% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in CGEM or PBYI? Puma Biotechnology received 508 more outperform votes than Cullinan Therapeutics when rated by MarketBeat users. However, 82.69% of users gave Cullinan Therapeutics an outperform vote while only 67.11% of users gave Puma Biotechnology an outperform vote. CompanyUnderperformOutperformCullinan TherapeuticsOutperform Votes4382.69% Underperform Votes917.31%Puma BiotechnologyOutperform Votes55167.11% Underperform Votes27032.89% Which has more risk & volatility, CGEM or PBYI? Cullinan Therapeutics has a beta of -0.16, indicating that its stock price is 116% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Which has stronger valuation & earnings, CGEM or PBYI? Puma Biotechnology has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCullinan TherapeuticsN/AN/A-$153.16M-$2.84-3.20Puma Biotechnology$235.60M0.60$21.59M$0.486.02 Is CGEM or PBYI more profitable? Puma Biotechnology has a net margin of 9.56% compared to Cullinan Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 41.60% beat Cullinan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cullinan TherapeuticsN/A -26.54% -25.32% Puma Biotechnology 9.56%41.60%10.71% Does the media favor CGEM or PBYI? In the previous week, Cullinan Therapeutics had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 2 mentions for Cullinan Therapeutics and 1 mentions for Puma Biotechnology. Cullinan Therapeutics' average media sentiment score of 0.32 beat Puma Biotechnology's score of 0.00 indicating that Cullinan Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Puma Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryPuma Biotechnology beats Cullinan Therapeutics on 10 of the 16 factors compared between the two stocks. Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBYI vs. The Competition Export to ExcelMetricPuma BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$142.41M$7.07B$5.81B$9.02BDividend YieldN/A2.87%4.78%3.85%P/E Ratio6.046.0426.2318.96Price / Sales0.60317.07453.4377.29Price / Cash4.1467.8344.0437.47Price / Book2.586.777.664.69Net Income$21.59M$138.11M$3.18B$245.69M7 Day Performance1.08%-1.51%-1.36%-1.85%1 Month Performance-2.99%-1.07%0.73%-1.54%1 Year Performance-55.59%-2.80%17.60%14.60% Puma Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBYIPuma Biotechnology3.7562 of 5 stars$2.90-0.7%$7.00+141.4%-57.0%$142.36M$235.60M6.04200Upcoming EarningsNews CoverageCGEMCullinan Therapeutics2.3334 of 5 stars$9.53-0.6%$32.50+241.0%-47.4%$554.93MN/A-3.3630AUTLAutolus Therapeutics2.9263 of 5 stars$2.04+5.2%$10.40+409.8%-70.7%$542.82M$1.70M-1.69330Negative NewsVALNValneva2.0254 of 5 stars$6.67-14.4%$17.50+162.4%+9.6%$542.01M$158.54M-51.31700Analyst ForecastAnalyst RevisionGap DownHigh Trading VolumeXERSXeris Biopharma3.729 of 5 stars$3.59-0.3%$5.15+43.5%+25.6%$535.20M$163.91M-7.98290News CoveragePositive NewsMAZEMaze TherapeuticsN/A$12.00+6.0%N/AN/A$525.36MN/A0.00121Gap UpTECXTectonic Therapeutic2.7559 of 5 stars$35.57+3.3%$80.50+126.3%N/A$524.76MN/A-6.04120MGTXMeiraGTx4.296 of 5 stars$6.70+1.5%$23.50+250.7%+15.8%$523.61M$14.02M-5.54300News CoverageGap UpMLYSMineralys Therapeutics2.6218 of 5 stars$10.24+0.4%$27.00+163.7%-37.7%$509.65MN/A-3.1328TRDAEntrada Therapeutics3.3103 of 5 stars$13.44+6.4%$25.67+91.0%-4.0%$502.93M$215.23M8.45110Positive NewsRNACCartesian Therapeutics1.7124 of 5 stars$19.67+3.4%$42.86+117.9%-11.9%$500.01M$26M-0.3764 Related Companies and Tools Related Companies Cullinan Therapeutics Competitors Autolus Therapeutics Competitors Valneva Competitors Xeris Biopharma Competitors Maze Therapeutics Competitors Tectonic Therapeutic Competitors MeiraGTx Competitors Mineralys Therapeutics Competitors Entrada Therapeutics Competitors Cartesian Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PBYI) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
